Drug · DIN 02279401
REVATIO
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 11, 2023; first marketed June 12, 2006.
- Drug Identification Number (DIN)
- 02279401
- Company (DIN owner)
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Antihypertensives for pulmonary arterial hypertension C02KX
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SILDENAFIL (SILDENAFIL CITRATE) | 20 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 11, 2023: NOC 31596New Drug Submission (NDS) · Administrative: Change in Product Ownership
- June 5, 2020: NOC 23738New Drug Submission (NDS) · Administrative: Change in Product Ownership, Updates to the product monograph,Inner and outer labels and package insert.
- May 26, 2006: NOC 7982New Drug Submission (NDS)
Other DINs named REVATIO
- DIN 02341611 · Marketed